Entity
  • AviadoBio

    Created in 2019


  • Trend leader (A+)
    Existing signals make this entity one of the most dynamic startups
  • Social networks

    12,586
  • Activities

  • Technologies

  • Entity types

  • Location

    20 Water Street, 11 Park Dr, London E14 9GG, UK

    London

    United Kingdom

  • Employees

    Scale: 11-50

    Estimated: 74

  • Engaged catalyst

    1
    0 0
  • Added in Motherbase

    6 months, 1 week ago
Description
  • Value proposition

    A revolution in gene therapy for neurodegenerative disorders.


    At AviadoBio, we are relentlessly chasing cures by translating groundbreaking science and precision delivery into life-changing medicines for people living with frontotemporal dementia (FTD) and amyotrophic lateral sclerosis (ALS).

    With our deep understanding of the brain and our suite of proprietary gene therapy platforms and delivery technologies, we are working relentlessly to overcome the challenges of delivering the right drug to the right place. Our innovative, neuroanatomy-led approach is designed to maximize the therapeutic potential of gene therapy to halt or potentially reverse neurodegenerative diseases. The Company’s technology is based on pioneering research from King’s College London and the UK Dementia Research Institute.

Catalyst interactions
Catalyst TypeTweets Articles
Astellas Pharma
Astellas Pharma
Pharmaceutical
Astellas Pharma
Pharmaceutical
Other

18 Jan 2025


Social network dynamics
Similar entities
BETA
Loading...
Loading...